Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neurocrine Biosciences (NBIX) EBIT (2016 - 2025)

Neurocrine Biosciences (NBIX) has disclosed EBIT for 15 consecutive years, with $210.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBIT rose 48.52% year-over-year to $210.9 million, compared with a TTM value of $619.1 million through Dec 2025, up 8.52%, and an annual FY2025 reading of $619.1 million, up 8.52% over the prior year.
  • EBIT was $210.9 million for Q4 2025 at Neurocrine Biosciences, down from $239.0 million in the prior quarter.
  • Across five years, EBIT topped out at $239.0 million in Q3 2025 and bottomed at -$114.2 million in Q1 2023.
  • Average EBIT over 4 years is $105.3 million, with a median of $141.2 million recorded in 2023.
  • The sharpest move saw EBIT surged 200.45% in 2021, then tumbled 76.23% in 2025.
  • Year by year, EBIT stood at $44.5 million in 2021, then soared by 237.75% to $150.3 million in 2023, then decreased by 5.52% to $142.0 million in 2024, then surged by 48.52% to $210.9 million in 2025.
  • Business Quant data shows EBIT for NBIX at $210.9 million in Q4 2025, $239.0 million in Q3 2025, and $145.6 million in Q2 2025.